Endpoints shares our FDA letter

Adding to the list of larger news outlets covering what APC is up to is Endpoints News (from the Financial Times). It wrote about our letter to the FDA that pointed out that semaglutide isn’t difficult to compound, despite erroneous claims by Novo Nordisk.

In its article on Lilly's introduction of DTC discounted vials of Zepbound, IHP included a great...

You’ve probably seen the news that Eli Lilly will begin selling Zepbound in vials by mail. What you...

The story this past Monday is one of the best media reports on compounding that we’ve seen. The...

Endpoints shares our FDA letter

Related posts

Inside Health Policy quotes Scott (again)

Scott on Lilly on GLP-1s on CBS

Joe Navarra on NBC Nightly News